Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. "Moderate" dose cyclophosphamide for severe aplastic anemia has significant toxicity and does not prevent relapse and clonal evolution

    ... a lower "moderate" dose, in combination with aggressive supportive care , to determine if severe infections might be avoided and hematologic ...

    Research Article last updated 09/24/2014 - 10:17am.

  2. Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes - Lingering Uncertainties and Emerging Possibilities

    ... sources and improvements in transplant technology and supportive care . Despite these advances, several issues, mostly centering on ...

    Research Article last updated 08/21/2014 - 9:28am.

  3. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

    ... leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. ...

    Research Article last updated 07/28/2014 - 10:43am.

  4. Myelodysplastic syndromes: challenges to improving patient and caregiver satisfaction

    ... (MDS) poses many challenges for physicians and patient care teams. Advances in the understanding of MDS biology have resulted in the ... of recently diagnosed patients with MDS still receive supportive care only. Interestingly, a survey performed in patients with ...

    Research Article last updated 07/31/2012 - 1:05pm.

  5. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

    ... many years, the main treatment option for MDS was best supportive care which alleviates symptoms, but has no effect on the natural course of ...

    Research Article last updated 10/11/2011 - 5:58pm.

  6. Azacitidine in lower-risk myelodysplastic syndromes.

    ... prolong overall survival (OS) compared with conventional care regimens in patients with higher-risk myelodysplastic syndromes ... rate (ORR) of 60% and a longer median OS compared with supportive care (44 vs 27 months). In a phase II study investigating ...

    Research Article last updated 10/11/2011 - 5:58pm.

  7. Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes.

    ... when analysis was restricted to 602 patients managed by supportive care . MK adversely affected survival in both poor and very poor karyotype ...

    Research Article last updated 06/20/2013 - 10:54am.

  8. How we treat lower risk myelodysplastic syndromes.

    ... mainly characterized by anemia in most cases. Supportive care , mainly red blood cell transfusions, remains an important ...

    Research Article last updated 05/14/2013 - 2:56pm.

  9. Prognosis of acute myeloid leukemia transformed from myelodysplastic syndromes: A multicenter retrospective study

    ... 189 AL-MDS patients. Ninety-four patients received best supportive care (BSC), and 94 patients received disease-modifying therapies (DMT) that ...

    Research Article last updated 04/02/2013 - 7:59am.

  10. How I treat acquired aplastic anemia

    ... immunosuppressive biologics and drugs, and supportive care . However, management of SAA patients remains challenging, both acutely ...

    Research Article last updated 07/30/2012 - 2:00pm.